Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes
Satyaki Sengupta, Sanjukta Das, Ângela C. Crespo, et al.
Nature Cancer (2022) Vol. 3, Iss. 10, pp. 1228-1246
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Children's Oncology Group's 2023 blueprint for research: Neuroblastoma
Rochelle Bagatell, Steven G. DuBois, Arlene Naranjo, et al.
Pediatric Blood & Cancer (2023) Vol. 70, Iss. S6
Open Access | Times Cited: 26
Multiomics Analysis Reveals Neuroblastoma Molecular Signature Predicting Risk Stratification and Tumor Microenvironment Differences
Xing Zhou, Zhaokai Zhou, Xiaohan Qin, et al.
Journal of Proteome Research (2025)
Closed Access
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets
Nathan M. Kendsersky, Michal Odrobina, Nathaniel W. Mabe, et al.
Neuro-Oncology (2025)
Open Access
ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma.
Federica Lorenzi, Sina Jostes, Qiong Gao, et al.
Cancer Letters (2025), pp. 217495-217495
Closed Access
EDF1 accelerates ganglioside GD3 accumulation to boost CD52-mediated CD8+ T cell dysfunction in neuroblastoma
Di Li, Meng Li, Zhenjian Zhuo, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance
Junpeng Fan, Funian Lu, Tianyu Qin, et al.
Nature Genetics (2023) Vol. 55, Iss. 12, pp. 2175-2188
Open Access | Times Cited: 15
Identification and characterization of chemotherapy resistant high-risk neuroblastoma persister cells
Liron D. Grossmann, Chia-Hui Chen, Yasin Uzun, et al.
Cancer Discovery (2024), pp. OF1-OF20
Open Access | Times Cited: 4
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
Annelisa M. Cornel, Ester Dünnebach, Damon A. Hofman, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005002-e005002
Open Access | Times Cited: 23
Targeting the myeloid microenvironment in neuroblastoma
Marjolein C. Stip, Loes Teeuwen, Miranda P. Dierselhuis, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 12
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers
Wan Ching Lim, Maria Eugénia Marques Da Costa, Karine Godefroy, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 4
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification
Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 11, pp. 1841-1854
Open Access | Times Cited: 4
Silencing of the PHLDA1 leads to global proteome changes and differentiation pathways of human neuroblastoma cells
Beata Bugara, Małgorzata Durbas, M. Kudrycka, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Bioactive sphingolipids as emerging targets for signal transduction in cancer development
Wentao Jia, Jiaying Yuan, Jinbo Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189176-189176
Closed Access | Times Cited: 3
Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
Cristina Larrosa, Jaume Mora, Nai‐Kong V. Cheung
Cancers (2023) Vol. 15, Iss. 14, pp. 3729-3729
Open Access | Times Cited: 8
Lineage Plasticity: The New Cancer Hallmark on the Block
Arnav Mehta, Ben Z. Stanger
Cancer Research (2023) Vol. 84, Iss. 2, pp. 184-191
Open Access | Times Cited: 8
Defining neuroblastoma: from origin to precision medicine
Lourdes Sainero‐Alcolado, Tomas Sjöberg Bexelius, Giuseppe Santopolo, et al.
Neuro-Oncology (2024) Vol. 26, Iss. 12, pp. 2174-2192
Open Access | Times Cited: 2
Patient-derived models: Advanced tools for precision medicine in neuroblastoma
Kristina Aaltonen, Katarzyna Radke, Aleksandra Adamska, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 7
Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors
Apexa Modi, Gonzalo López, Karina L. Conkrite, et al.
Cancer Research (2023) Vol. 83, Iss. 20, pp. 3462-3477
Closed Access | Times Cited: 7
Adrenergic and mesenchymal signatures are identifiable in cell‐free DNA and correlate with metastatic disease burden in children with neuroblastoma
Omar R. Vayani, Maria E. Kaufman, Kelley Moore, et al.
Pediatric Blood & Cancer (2023) Vol. 71, Iss. 1
Open Access | Times Cited: 6
Heterogeneity and transcriptional drivers of triple-negative breast cancer
Bojana Jovanović, Daniel Temko, Laura E. Stevens, et al.
Cell Reports (2023) Vol. 42, Iss. 12, pp. 113564-113564
Open Access | Times Cited: 6
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1
Annelisa M. Cornel, Loutje van der Sman, Jip T. van Dinter, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e007538-e007538
Open Access | Times Cited: 1
Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells
Sabina Di Matteo, Maria Teresa Bilotta, Andrea Pelosi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy
Lauren Zebertavage, Allison Schopf, Megan Nielsen, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2561-2561
Open Access | Times Cited: 1
A potassium‐chloride co‐transporter with altered genome architecture functions as a suppressor in glioma
Hongwei Liu, Zhouyang Pan, Xuelei Lin, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 9
Open Access | Times Cited: 1
USP44 Overexpression Drives a MYC-Like Gene Expression Program in Neuroblastoma through Epigenetic Reprogramming
Thomas L. Ekstrom, Sajjad Hussain, Tibor Bedekovics, et al.
Molecular Cancer Research (2024) Vol. 22, Iss. 9, pp. 812-825
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top